Caitlin Camfield, Yolanda N Evans, Raaka G Kumbhakar
{"title":"青少年和年轻成年人的艾滋病毒暴露前预防：最新情况。","authors":"Caitlin Camfield, Yolanda N Evans, Raaka G Kumbhakar","doi":"10.1097/MOP.0000000000001357","DOIUrl":null,"url":null,"abstract":"PURPOSE OF REVIEW\nThis review provides an update of evidence for HIV preexposure prophylaxis (PrEP), including efficacy and safety of newly available medications. It discusses barriers to care that are unique to adolescents and young adults as well as interventions that may help increase uptake, adherence, and retention in care.\n\n\nRECENT FINDINGS\nTenofovir alafenamide-emtricitabine and cabotegravir are both newly approved medications for the prevention of HIV and are well tolerated and effective for adolescents. These medications, along with tenofovir disoproxil-emtricitabine, offer a variety of PrEP options to choose from.\n\n\nSUMMARY\nAdolescents and young adults have many options when it comes to HIV prevention, but barriers persist in terms of uptake and adherence to PrEP and retention in care. Technology-based interventions, provider education, navigation support, and multiple access options are all tools to help increase PrEP use in young people.","PeriodicalId":10985,"journal":{"name":"Current opinion in pediatrics","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIV preexposure prophylaxis in adolescents and young adults: an update.\",\"authors\":\"Caitlin Camfield, Yolanda N Evans, Raaka G Kumbhakar\",\"doi\":\"10.1097/MOP.0000000000001357\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PURPOSE OF REVIEW\\nThis review provides an update of evidence for HIV preexposure prophylaxis (PrEP), including efficacy and safety of newly available medications. It discusses barriers to care that are unique to adolescents and young adults as well as interventions that may help increase uptake, adherence, and retention in care.\\n\\n\\nRECENT FINDINGS\\nTenofovir alafenamide-emtricitabine and cabotegravir are both newly approved medications for the prevention of HIV and are well tolerated and effective for adolescents. These medications, along with tenofovir disoproxil-emtricitabine, offer a variety of PrEP options to choose from.\\n\\n\\nSUMMARY\\nAdolescents and young adults have many options when it comes to HIV prevention, but barriers persist in terms of uptake and adherence to PrEP and retention in care. Technology-based interventions, provider education, navigation support, and multiple access options are all tools to help increase PrEP use in young people.\",\"PeriodicalId\":10985,\"journal\":{\"name\":\"Current opinion in pediatrics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-04-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in pediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MOP.0000000000001357\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOP.0000000000001357","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
摘要
综述目的本综述提供了有关艾滋病暴露前预防（PrEP）的最新证据，包括新上市药物的疗效和安全性。本综述还讨论了青少年和年轻成年人在接受治疗时遇到的障碍，以及有助于提高接受率、依从性和保留率的干预措施。这些药物与替诺福韦酯-恩曲他滨一起提供了多种 PrEP 选择。摘要青少年和年轻成年人在预防 HIV 方面有很多选择，但在接受和坚持 PrEP 以及继续接受护理方面仍存在障碍。以技术为基础的干预措施、医疗服务提供者教育、导航支持和多种获取方式都是有助于提高 PrEP 在年轻人中使用率的工具。
HIV preexposure prophylaxis in adolescents and young adults: an update.
PURPOSE OF REVIEW
This review provides an update of evidence for HIV preexposure prophylaxis (PrEP), including efficacy and safety of newly available medications. It discusses barriers to care that are unique to adolescents and young adults as well as interventions that may help increase uptake, adherence, and retention in care.
RECENT FINDINGS
Tenofovir alafenamide-emtricitabine and cabotegravir are both newly approved medications for the prevention of HIV and are well tolerated and effective for adolescents. These medications, along with tenofovir disoproxil-emtricitabine, offer a variety of PrEP options to choose from.
SUMMARY
Adolescents and young adults have many options when it comes to HIV prevention, but barriers persist in terms of uptake and adherence to PrEP and retention in care. Technology-based interventions, provider education, navigation support, and multiple access options are all tools to help increase PrEP use in young people.
期刊介绍：
Current Opinion in Pediatrics is a reader-friendly resource which allows the reader to keep up-to-date with the most important advances in the pediatric field. Each issue of Current Opinion in Pediatrics contains three main sections delivering a diverse and comprehensive cover of all key issues related to pediatrics; including genetics, therapeutics and toxicology, adolescent medicine, neonatology and perinatology, and orthopedics. Unique to Current Opinion in Pediatrics is the office pediatrics section which appears in every issue and covers popular topics such as fever, immunization and ADHD. Current Opinion in Pediatrics is an indispensable journal for the busy clinician, researcher or student.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
